Sequence Bio research posters selected for presentation at ASHG 2023

November 1, 2023

Sequence Bio, a biotechnology company researching the founder effect in Newfoundland and Labrador to accelerate novel drug target discovery, is pleased to announce that it was selected to present two research posters at the American Society of Human Genetics’ (ASHG) 2023 meeting, the largest human genetics and genomics meeting and exposition in the world.

In their posters, members of Sequence Bio’s Research and Data Science team shared insights from the company’s flagship genetic research study in Newfoundland and Labrador, the NL Genome Project:

  • Investigating the contrast in ROH between Newfoundland founder population and ancestral British-Irish population based on 1000 Genomes data, authored by Sedat Demiriz, Meg MacMillan, Tiffany Furneaux, and Bari Ballew.

  • A statistical approach for detecting trends in underpowered genome-wide association studies, authored by Meg MacMillan, Cam Nugent, Sedat Demiriz, Tiffany Furneaux, and Bari Ballew

Sequence Bio’s posters were presented in person at ASHG 2023, held November 1-5, 2023, in Washington, DC. 

About ASHG 2023

The ASHG Annual Meeting, produced by the American Society of Human Genetics (ASHG), is the largest human genetics and genomics meeting and exposition in the world. Held in October, it provides a forum for the presentation and discussion of cutting-edge science in all areas of human genetics. Highlights include invited symposia; abstract-driven plenary, platform, and poster sessions; education/trainee workshops; and career opportunities and networking events.

For more information, please visit

For additional information please contact

Chris McDonald
VP, Market Development
+1-800-296-3481 x708